Details for Patent: 5,028,432

Summary for Patent: 5,028,432

Title:	Pharmaceutical capsules containing panetidine
Abstract:	The invention relates to a pharmaceutical composition in the form of a gelatin capsules consisting of a filling containing as active ingredient ranitidine or a physiologically acceptable salt thereof surrounded by a gelatin shell. The filling is formulated based on a non-aqueous matrix consisting of at least one fatty acid glyceride and/or mineral oil or paraffin. Preferably the matrix contains at least one surfactant. The matrix is essentially hydrophobic in character but is also sufficiently hydrophilic to permit dispersion and dissolution of the capsule filling in the gastrointenstinal tract.
Inventor(s):	Chopra; Sham K. (Bramalea, CA), Makadia; Tribhovan T. (Mississauga, CA)
Assignee:	Glaxo Canada, Inc. (CA)
Application Number:	07/482,903
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 5,028,432

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 5,028,432

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	8904182	Feb 23, 1989

International Family Members for US Patent 5,028,432

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	401727
Austria	A42190
Australia	5007390